Pharmaceutical companies fund most clinical research, shaping medical science to favor profit over patients. How does industry influence distorted outcomes and what can be done to ensure independent, transparent research?<\/p>\n
<\/p>\n
Whether facing a global pandemic, navigating chronic illness or responding to environmental threats, society looks to medical science to heal, protect and advance our collective well-being.<\/p>\n
But beneath the surface of peer-reviewed journals and cutting-edge discoveries lies a troubling reality: the pharmaceutical industry. The industry is worth\u00a0over<\/a>\u00a0$1.6 trillion globally, according to Statista, and has an outsized influence on the direction, design and outcomes of scientific research.<\/p>\n By funding a significant portion of clinical studies, pharmaceutical companies can shape not only which questions get asked but also how results are interpreted and shared.<\/p>\n This raises a pressing question where it must be established if the industry is driven by profit and who is science really serving? Is it the patients or shareholders?<\/p>\n More than half of all clinical trials are now\u00a0funded<\/a>\u00a0by pharmaceutical companies, according to JAMA network. At first glance, this might seem like a win-win situation. Private funding supports innovation, and the public reaps the medical benefits, however, when profit becomes the driving force, priorities shift.<\/p>\n Pharmaceutical companies are far more likely to fund studies for drugs that promise high financial returns, even when cheaper, more effective alternatives already exist.<\/p>\n Research<\/a>\u00a0into rare diseases, non-patentable treatments or preventive care are areas that could profoundly benefit public health and remain\u00a0underfunded<\/a>. The reason is simple. There is no money to cure what affects only a few or to prevent disease when treatment is more profitable.<\/p>\n <\/p>\n <\/p>\nResearch for Sale<\/strong><\/h3>\n